Abstracts Archive - Page 2074 of 2607 - ACR Meeting Abstracts

Abstract Number: 2399 • 2014 ACR/ARHP Annual Meeting
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey
Gerolamo Bianchi¹, Antonio Carletto², Oscar Massimiliano Epis³, Crescenzio Scioscia⁴, Angelo Semeraro⁵, Laura Bianchino⁶, Laura Bazzichi⁷, Giovanni Lapadula⁸, Luigi Sinigaglia⁹ and Andrea Lo Monaco¹⁰, ¹Div Reumatologia, ASL3 Genovese, Genoa, Italy, ²Dipartimento di Medicina,U.O. Complessa di Reumatologia ,Azienda Ospedaliera Universitaria di Verona, Verona, Italy, ³Rheumatology Unit, Niguarda Ca' Granda Hospital, Milan, Italy, ⁴University of Bari, Bari, Italy, ⁵P.O. “Valle d'Itria, Martina Franca, Italy, ⁶Roche Spa., Monza, Italy, ⁷University of Pisa, Rheumatology Unit, Pisa, Italy, ⁸DIM, Rheumatology Unit, Bari, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Medical Sciences-Rheumatology Unit, Azienda ospedaliero-universitaria Sant'Anna, Ferrara, Italy
Background/Purpose Approximately 50% of patients (pts) with chronic diseases are non-adherent to the therapeutic regimen assigned. In pts with rheumatoid arthritis (RA), the non-adherence to…
Abstract Number: 2400 • 2014 ACR/ARHP Annual Meeting
Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity
Chamaida Plasencia-Rodriguez¹, G. J. Wolbink², Charlotte L. M. Krieckaert², Eva L. Kneepkens³, Samina Turk⁴, Maria Gema Bonilla⁵, Alejandro Villalba¹, Diana Peiteado¹, Laura Nuño⁶, Mike T. Nurmohamed², Theo Rispens⁷, Desiree van der Kleij⁸, Teresa Jurado⁹, Emilio Martín-Mola¹⁰, Dora Pascual-Salcedo¹¹ and Alejandro Balsa¹², ¹Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ²Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ³Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, ⁴Reade, Amsterdam, Netherlands, ⁵Rheumatology Unit, La Paz University Hospital, Madrid, Spain, ⁶Hospital La Paz-IdiPaz, Madrid, Spain, ⁷Sanquin Research, Amsterdam, Netherlands, ⁸Sanquin Diagnostic Services, Amsterdam, Netherlands, ⁹Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹¹Immunology, La Paz University Hospital, Madrid, Spain, ¹²Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain
Background/Purpose: There is a growing interest about optimization of biological therapies but for now no strong evidence is available to support a tapering strategy in…
Abstract Number: 2401 • 2014 ACR/ARHP Annual Meeting
Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis: The Best Target for Therapy?
Liam O'Neil¹, Carol A. Hitchon², David B. Robinson³, Navjot Dhindsa¹, Hani El-Gabalawy³ and Christine A. Peschken⁴, ¹Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³Arthritis Centre, University of Manitoba, Winnipeg, MB, Canada, ⁴University of Manitoba, Canada, Winnipeg, MB, Canada
Background/Purpose: Severe disease and poor outcomes have been described in First Nation (FN) patients with Rheumatoid Arthritis (RA). We examined the contributions of interrupted and…
Abstract Number: 2402 • 2014 ACR/ARHP Annual Meeting
Evaluation of Perceived Self-Efficacy, Learned Helplessness and Functional Capacity in Patients with Rheumatoid Arthritis
Facundo Vergara¹, Emmanuel Bertiller², Celeste Orozco³, Javier Rosa¹, Erika Catay¹, Maria de los Angeles Gallardo⁴, Emilce Schneeberger⁵, Maria Victoria Garcia¹, Gustavo Citera⁶, Marcos G. Rosemffet⁷, Mirtha Sabelli¹ and Enrique R. Soriano⁸, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Instituto Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, BUENOS AIRES, Argentina, ⁵Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁶Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁷Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁸Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina
Background/Purpose: Rheumatoid Arthritis (RA) is an inflammatory chronic disease that involves cognitive and emotional aspects of patients, from the beginning of diagnosis. One relevant cognitive…
Abstract Number: 2403 • 2014 ACR/ARHP Annual Meeting
From Early Arthritis Clinic to Remission Clinic: Short-Term Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in DMARD-Induced SDAI-Remission during Drug-Free Follow-up
Antonio Manzo¹, Francesca Benaglio¹, Garifallia Sakellariou¹, Martina Scarabelli¹, Elisa Binda¹, Barbara Vitolo¹, Serena Bugatti¹, Roberto Caporali² and Carlomaurizio Montecucco¹, ¹Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy, ²Division of Rheumatology, Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S.Matteo Foundation/University of Pavia, Pavia, Italy
Background/Purpose The introduction of DAS-driven intensive treatment strategies in early rheumatoid arthritis (RA) has considerably improved outcome and patients’ quality of life. Previous studies have…
Abstract Number: 2404 • 2014 ACR/ARHP Annual Meeting
RA Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long-Term Response When Switched to SC MTX Monotherapy
Anthony Hammond¹ and Michael Batley², ¹Rheumatology, Maidstone and Tunbridge Wells NHS Trust, Kent TN13 2JD, United Kingdom, ²Rheumatology, Maidstone and Tunbridge Wells Hospital, Kent, United Kingdom
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) therapy, but many patients do not achieve adequate response to oral therapy for reasons of…
Abstract Number: 2405 • 2014 ACR/ARHP Annual Meeting
Quality of Patient- Clinician Communication in a Diverse Cohort of Adults with Rheumatoid Arthritis
Jennifer Barton¹, Chris Tonner², Laura Trupin¹, Patricia P. Katz³ and Edward H. Yelin⁴, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²3333 California Street, Box 09, University of California, San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, CA, ⁴Arthritis Research Group, University of California, San Francisco, San Francisco, CA
Background/Purpose: To assess correlates of the quality of patient-clinician communication in a diverse cohort of adults with rheumatoid arthritis (RA). Methods: Data were obtained through…
Abstract Number: 2406 • 2014 ACR/ARHP Annual Meeting
Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics
J. Harnett¹, D. Wiederkehr¹, R. Gerber², D. Gruben², J. Bourret³ and A. Koenig³, ¹Pfizer Inc, New York, NY, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Injectable biologics are commonly used to treat patients (pts) with moderate to severe rheumatoid arthritis (RA); the frequency with which they are prescribed but…
Abstract Number: 2407 • 2014 ACR/ARHP Annual Meeting
Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Laurent Chanroux and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom
Background/Purpose: It is generally thought that the early treatment of patients with rheumatoid arthritis (RA) leads to improved patient outcomes over time. Our study aims…
Abstract Number: 2408 • 2014 ACR/ARHP Annual Meeting
Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity
Francesca Ometto¹, Costantino Botsios², Livio Bernardi¹, Bernd Raffeiner^2,3, Leonardo Punzi⁴ and Andrea Doria⁴, ¹Rheumatology Unit, Department of Medicine -DIMED, University of Padova, PADOVA, Italy, ²Rheumatology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy, ³Department of Medicine, Rheumatology - General Hospital Bolzano, Bolzano, Italy, ⁴Department of Medicine - DIMED, University of Padova, Padova, Italy
Background/Purpose Rheumatoid arthritis (RA) flares are predictive of structural damage even in case of stable disease course. No definition for flare has been validated to…
Abstract Number: 2409 • 2014 ACR/ARHP Annual Meeting
Omega-3 Fatty Acids and Mediterranean Diet As Complimentary Therapies for Rheumatoid Arthritis
Ana Carolina Araújo¹, Maria Francisca Moraes-Fontes¹, Lèlita Santos² and Nuno Riso¹, ¹Serviço de Medicina 2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ²Serviço de Medicina Interna, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal
Background/Purpose Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial joints, often with a progressive and destructive course, leading to disability. Nowadays, there…
Abstract Number: 2410 • 2014 ACR/ARHP Annual Meeting
Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort
Bindee Kuriya¹, Daming Lin², Cheryl Barnabe³, Gilles Boire⁴, Boulos Haraoui⁵, Carol Hitchon⁶, Shahin Jamal⁷, J. Carter Thorne⁸, Diane Tin⁹, Janet E. Pope¹⁰, Edward Keystone¹¹ and Vivian P. Bykerk¹², ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁵Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ⁶Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Rheumatology, Vancouver Coastal Health, Vancouver, BC, Canada, ⁸Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Medicine, Western University, London, ON, Canada, ¹¹University of Toronto and Mount Sinai Hospital, Toronto, ON, Canada, ¹²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: To describe working status in an ERA population in the first year of disease, and factors associated with improved work productivity. Methods: Patients in…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 2412 • 2014 ACR/ARHP Annual Meeting
Regime of Use of Rituximab in Patients with Rheumatoid Arthritis in Daily Clinical Practice
Leticia Merino-Meléndez¹, Irene Llorente², Santos Castañeda³, Teresa Velasco², Luis Sala-Icardo⁴, Rosario Garcia-Vicuña⁴, Alberto Garcia-Vadillo⁵, Juan P. López-Bote⁴, Jorge López-López⁶, Federico Herrera⁶, Cecilia Muñoz-Calleja⁶, JM Álvaro-Gracia² and Isidoro González-Alvaro⁴, ¹Rheumatology Department, Hospital Universitario de La Princesa, Madrid, Spain, ²Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ³Rheumatology, Hospital Universitario de La Princesa, IISP, Madrid, Spain, ⁴Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁵Servicio de Reumatología, Hospital Universitario de La Princesa, Madrid, Spain, ⁶Immunology, Hospital Universitario de La Princesa, Madrid, Spain
Background/Purpose: The recommended therapeutic regime for Rituximab (RTX) in Rheumatoid Arthritis (RA), according to prescribing information, includes two 1000-milligram infusions given two weeks apart, every…
Abstract Number: 2373 • 2014 ACR/ARHP Annual Meeting
Compliance in the Rheumatoid Arthritis Comparison of Active Therapies Trial: Triple Vs Etanercept
Sarah Leatherman¹, Hongsheng Wu^2,3, Edward Keystone⁴, Mary Brophy¹ and James O'Dell^5,6, ¹MAVERIC CSPCC (151MAV), VA Boston Healthcare System, Boston, MA, ²VA Boston Healthcare System, Boston, MA, ³Computer Science and Systems, Wentworth Institute of Technology, Boston, MA, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵VA Nebraska-Western Iowa Health Care System, Omaha, NE, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose In the 48-week, double-blinded, noninferiority RACAT trial, 353 methotrexate suboptimal responders were randomized to two treatment strategies, either the addition of sulfasalazine and hydroxychloroquine…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].